Novo Nordisk's Q1 showed robust sales/EPS growth, fueled by soaring GLP-1 demand in a multi-billion dollar market. Read why I ...

Hedge fund aims to influence CEO appointment as drugmaker battles share price slump and competition from Eli Lilly.

Novo Nordisk (NVO) shares hit their highest level in over two months following a Financial Times report that activist hedge ...

--Activist hedge fund Parvus Asset Management is building a stake in Ozempic-maker Novo Nordisk as the drugmaker hunts for a new chief executive following a share-price slump, according to the ...

These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

Hims & Hers (NYSE: HIMS) stock, a prominent player in the booming telehealth sector, has undeniably captured significant investor attention recently. Perhaps you, like many others, have been caught up ...

Moelis threw himself into action, developing a reputation as one of the best connected bankers on Wall Street. In 2014, Moelis & Company went public and it now has a market capitalisation of more than ...

McDonald's stock was cut from buy to sell over a potential double-digit loss in sales due to weight-loss drugs.

ABBV eyes $24.7 billion from Skyrizi and Rinvoq in 2025 as ex-Humira growth offsets sharp sales drop post-U.S. patent loss.

In what Guggenheim Partners called one of Metsera’s “critical program milestones” this year, its ultra-long-acting amylin ...